Clearmind Medicine (CMND)
Develops non-hallucinogenic MEAI treatments for alcohol use disorder and related conditions.
Something off on this page? Send us feedback.
Develops MEAI-based, non-hallucinogenic medicines and related products, led by CMND-100 for alcohol use disorder. Its asset-heavy model relies on outsourced research and trials, and it has no approved product or product-sales revenue.
Develops non-hallucinogenic, psychedelic-derived compounds, led by oral CMND-100, a MEAI candidate in Phase I/II testing for alcohol use disorder. Additional work includes intranasal MEAI, preclinical metabolic and weight-management research, an MEAI-based alcohol-substitute beverage, and discovery-stage programs for addiction and mental-health conditions.
Operates as a Canadian-incorporated company headquartered in Vancouver, with research and development primarily in Israel and clinical sites in Israel and the United States. A small internal team coordinates academic licenses, external laboratories, contract research organizations, clinical-supply vendors, and trial sites. The business has no approved products or product-sales revenue; progress depends on clinical evidence, regulatory approvals, external providers, academic licenses, and future financing.
Company facts
No analyst consensus on record.
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Apr 30, 2026Cash & short-term investments $13.6M · Total debt $85.6K · Total assets $14.5M · Shareholders' equity $11.5M
- Revenue
- $0
- Operating income
- −$1.6M
- Net income
- −$2.0M
No dividends on record.
| Institutions4 holders · as of Mar 31, 2026 | 1,138.28% | 4.5K ADS | |
| Adds to | 1,138.28% |
395 ADS (1 ADS = 40 ordinary shares) as of Sep 3, 2026 · institutions as of Mar 31, 2026 · holders as of their latest filing
Two share counts disagree (395 in the company's Sep 3, 2026 report, 1.49M elsewhere); stakes use the report.
These groups come from separate filings that can overlap, so they add to 1,138.28%; nothing is left for Other.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Evidence |
|---|---|---|---|
XTX Topco LtdInstitution | 549.22% | 21,694 ADS | 13Fas of Mar 31, 2026 |
HRT Financial LPInstitution | 402.78% | 15,910 ADS | 13Fas of Mar 31, 2026 |
Advisorshares Investments LLCInstitution | 186.25% | 7,357 ADS | 13Fas of Mar 31, 2026 |
UBS Group AGInstitution | 0.03% | 1 ADS | 13Fas of Mar 31, 2026 |
AdvisorShares TrustInstitution | —5.48% of class, as filed | — | 13Gfiled Feb 14, 2024 ↗ |
| See all 11 → | |||
13F — a manager's quarterly holdings · 13D/13G — an ownership statement filed at 5% or more
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Jun 16, 2026 | HRT Financial LP | 10 percent owner | −22,139 | $3.31 |
| Jun 15, 2026 | HRT Financial LP | 10 percent owner | −3,183 | $3.32 |
| Jun 12, 2026 | HRT Financial LP | 10 percent owner | −2,102 | $3.36 |
| Jun 11, 2026 | HRT Financial LP | 10 percent owner | −225,191 | $0.1230 |
| Jun 10, 2026 | HRT Financial LP | 10 percent owner | +2,159,052 | $0.1530 |
- Alkermes
Approved monthly medication with entrenched AUD market access.
- Atai Beckley
Intranasal 5-MeO-DMT program for AUD.
- Adial Pharmaceuticals
Phase 3 precision oral treatment for AUD.
ComparePre-market
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Clearmind Medicine | $1.75 | −6.11% | $2.7M | — | — | — | — |
| Alkermes | $47.74 | +1.14% | $8.01B | 124.6 | — | 4.8 | +27.0% |
| Atai Beckley | $7.32 | −0.39% | $2.72B | — | — | 607.9 | +137.0% |
| Adial Pharmaceuticals | $6.17 | −3.59% | $6.1M | — | — | — | — |
| Median | 124.6 | — | 306.4 | +82.0% |